Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2025)

Vivos Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $1.3 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.3 million (changed N/A YoY), and the annual figure for FY2025 was $1.3 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $1.3 million at Vivos Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.2 million in Q2 2023 to a low of $101000.0 in Q1 2022.
  • The 3-year median for Other Non-Current Liabilities is $1.3 million (2023), against an average of $1.2 million.
  • Peak annual rise in Other Non-Current Liabilities hit 1219.8% in 2023, while the deepest fall reached 1219.8% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $101000.0 in 2022, then surged by 494.06% to $600000.0 in 2023, then skyrocketed by 116.67% to $1.3 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.3 million, $1.4 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.